Clinical trial
Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients
NCT00044525 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00044525 |
|---|---|
| Title | Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients |
| Official title | An Uncontrolled Phase II Study Evaluating the Efficacy and Safety of Intravenous BAY59-8862 in Patients With Taxane-Resistant Metastatic Breast Cancer |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Breast Cancer, Metastatic |
| Intervention type | Drug |
| Interventions | BAY59-8862 (Cytotoxic Taxane) |
| Enrollment | 82 |
| Start date | Apr 1, 2002 |
| Primary completion | Feb 1, 2004 |
| Completion | Feb 1, 2004 |
| First posted | Sep 4, 2002 |
| Last update posted | Dec 23, 2014 |
| Countries | Germany, Greece, Israel, Italy, Poland, Switzerland, United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: